Central Nervous System Collaboration and Licensing Deals 2019-2024


Central Nervous System Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2024

Publication date
April 2024
Number of pages
Product type
Research report
Report edition

Central Nervous System Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the central nervous system deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 1,364 central nervous system deals from 2019 to 2024.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of central nervous system dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in central nervous system dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the central nervous system field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in central nervous system dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of central nervous system deals signed and announced since 2019 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of central nervous system deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in central nervous system deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


Key benefits

Central Nervous System Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2019
  • Browse central nervous system collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time


Report scope

Central Nervous System Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of central nervous system trends and structure of deals entered into by leading biopharma companies worldwide.

Central Nervous System Collaboration and Licensing Deals includes:

  • Trends in central nervous system dealmaking in the biopharma industry
  • Overview of collaboration and licensing deal structure
  • Directory of central nervous system deal records covering pharmaceutical and biotechnology
  • The leading central nervous system deals by value
  • Most active central nervous system licensing dealmakers

In Central Nervous System Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Central Nervous System Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Central Nervous System Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2019
  • Browse central nervous system collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in central nervous system dealmaking


2.1. Introduction

2.2. Central nervous system partnering over the years     

2.3. Central nervous system partnering by deal type

2.4. Central nervous system partnering by industry sector

2.5. Central nervous system partnering by stage of development

2.6. Central nervous system partnering by technology type

2.7. Central nervous system partnering by therapeutic indication


Chapter 3 – Financial deal terms for central nervous system partnering


3.1. Introduction

3.2. Disclosed financials terms for central nervous system partnering

3.3. Central nervous system partnering headline values

3.4. Central nervous system deal upfront payments

3.5. Central nervous system deal milestone payments

3.6. Central nervous system royalty rates


Chapter 4 – Leading central nervous system deals and dealmakers


4.1. Introduction

4.2. Most active in central nervous system partnering

4.3. List of most active dealmakers in central nervous system    

4.4. Top central nervous system deals by value


Chapter 5 – Central nervous system contract document directory


5.1. Introduction

5.2. Central nervous system partnering deals where contract document available


Chapter 6 – Central nervous system dealmaking by therapeutic target


6.1. Introduction

6.2. Deals by central nervous system therapeutic target


Deal Directory


Deal Directory – Central nervous system deals by company A-Z 2019 to 2024

Deal Directory  – Central nervous system deals by technology type 2019 to 2024


Deal type definitions


About Biopharma Research Ltd


Current Partnering

Current Agreements

Recent report titles from Current Partnering


Table of figures


Figure 1: Central nervous system partnering since 2019

Figure 2: Central nervous system partnering by deal type since 2019

Figure 3: Central nervous system partnering by industry sector since 2019

Figure 4: Central nervous system partnering by stage of development since 2019

Figure 5: Central nervous system partnering by technology type since 2019

Figure 6: Central nervous system partnering by indication since 2019

Figure 7: Central nervous system deals with a headline value

Figure 8: Central nervous system deals with upfront payment values

Figure 9: Central nervous system deals with milestone payment

Figure 10: Central nervous system deals with royalty rates

Figure 11: Active central nervous system dealmaking activity since 2019

Figure 12: Top central nervous system deals by value since 2019

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

3E Bioventures Capital, 3SBio, 4B Technologies, 4D Molecular Therapeutics, 4D Pharma, 4E Therapeutics, 23andMe, A*STAR’ Institute of Molecular and Cell Biology, Aachen University, Aardvark Therapeutics, Aarhus University Hospital, Abbott Laboratories, Abbvie, AbFero Pharmaceuticals, ABL Bio, Abliva, Abuse Deterrent Pharmaceuticals, ACADIA Pharmaceuticals, Acasti Pharma, Acelrx Pharmaceuticals, AC Immune, Aclarion, Aclipse Therapeutics, ACROBiosystems, Actimed Therapeutics, Acturum Life, Aculys Pharma, Acura Pharmaceuticals, AcuraStem, Adalvo, Adamas Pharmaceuticals, Addex Therapeutics, Adept Neuro, Adhera Therapeutics, Adimune, Adolore Biotherapeutics, Adventus Ventures, Aeromics, AffaMed Therapeutics, Affilogic, Affinia Therapeutics, AFT Pharmaceuticals, AgeX Therapeutics, Aguettant, Aichi Medical University, Aidoc, Aiforia Technologies, AimedBio, Aitia, Akome Biotech, Alamar Biosciences, Alberta Health Services, Albert Einstein College of Medicine, Alcyone Therapeutics, Alector, Alectos Therapeutics, Aleva Neurotherapeutics, Alexion Pharmaceuticals, Algernon Pharmaceuticals, Aliada Therapeutics, Aligning Science Against Parkinson’s, Allay Therapeutics, Allen Institute for Brain Science, Alligator Bioscience, Alloy Therapeutics, Alnylam Pharmaceuticals, Alora Pharmaceuticals, Alpha Cognition, ALS Association, AltaML, Altasciences, Altoida, Alto Neuroscience, Alume Biosciences, AlzeCure Pharma, Alzheimer's Drug Discovery Foundation, Amarna Therapeutics, Amathus Therapeutics, Ambiopharm, Ambra Health, American Academy of Neurology, American National Multiple Sclerosis Society, Amgen, Amicus Therapeutics, Amneal Pharmaceuticals, Amplifybio, Amydis, Amylyx Pharmaceuticals, Andelyn Biosciences, Angelini Pharma, Anima Biotech, Annogen, Annovis Bio, Antibe Therapeutics, Apellis Pharmaceuticals, Apic Bio, Aposense, AppliedVR, AprilBio, APRINOIA Therapeutics, Aptinyx, Aptorum Group, Aqilion, Aquestive Therapeutics, Aquinnah Pharmaceuticals, Aragen Life Sciences, Arbor Biotechnologies, Argobio, ARScience Biotherapeutics, Artiria Medical, Artizan Biosciences, Arvelle Therapeutics, Asahi Intecc, Asahi Kasei, Ashvattha Therapeutics, Asklepios Biopharmaceutical, Aspen Neuroscience, Assertio Therapeutics, Association for Frontotemporal Degeneration, Astellas Pharma, Astex Pharmaceuticals, AstraZeneca, Astrogen, ATAI Life Sciences, Atalanta Therapeutics, Atara Biotherapeutics, Athena GTX, Athinoula A Martinos Center for Biomedical Imaging, Athletic Heart Cardiac and Metabolic Testing, Aucta Pharmaceuticals, Aural Analytics, Aurora Spine, Autifony Therapeutics, Autobahn Therapeutics, Autotelic, Avalon Action Alliance, Avanos Medical, AveXis, AviadoBio, Avicanna, Avicenna Technology, Axial Biotherapeutics, Axoltis Pharma, AxoSim, Axsome Therapeutics, Baergic Bio, Banyan Biomarkers, Barrow Neurological Institute, Base4 Biotechnology, Baszucki Brain Research Fund, Battelle, Bayer, Baylor College, Beacon Biosignals, Beam Therapeutics, Beijing InnoCare Pharma, Belharra Therapeutics, BenevolentAI, Benuvia Therapeutics, Beth Israel Deaconess Medical Center, Bexson Biomedical, Bial, BIA Separations, BigHat Biosciences, Bio-Techne, BioArctic Neuroscience, biOasis Technologies, BioAxone BioSciences, Biobeat, Biocept, BioCircuit Technologies, Biocytogen, BioDelivery Sciences, Biodextris, Biodirection, Biofourmis, Biogen, Biohaven Pharmaceuticals, BioMarin Pharmaceutical, Biomedical Advanced Research and Development Authority, BioMed X Innovation Center, BioNxt Solutions, BioQ Pharma, Bioqube Ventures, Biorchestra, BioRestorative Therapies, Bioscience Pharma Partners, BioSyent Pharma, Blackford, Blackrock Microsystems, Blackrock Neurotech, Bloom Science, BlueRock Therapeutics, Blue Water Biotech, Boehringer Ingelheim, Boston University, BRAINBox Solutions, BrainLAB, Brainomix, BrainStorm Cell Therapeutics, Brain Trauma Foundation, Brain Treatment Center San Diego, Brammer Bio, Breakthrough Health, Breath of Life International, BridgeBio Pharma, Brigham and Women's Hospital, Bristol-Myers Squibb, Broad Institute, Brown University, Bruker, BT BeaMedical Technologies, C4 Therapeutics, C4X Discovery, Cala Health, California Institute for Regenerative Medicine, CAMP4 Therapeutics, Canadian Armed Forces, Canadian Neuromuscular Disease Registry, Cannassure Therapeutics, Cannex Scientific, Canon BioMedical, Canopy Growth, Cantabio Pharmaceuticals, Cap Alter Pharma, Capsida Biotherapeutics, Capsigen, Captor Therapeutics, Caraway Therapeutics, Cardiff University, Cardiovascular Solutions of Central Mississippi, CareTaker Medical, Carlsmed, Carna BioSciences, Carnegie Mellon University, Carrum Health, Case Western Reserve University, Casma Therapeutics, Catalent, Catalyst Pharmaceuticals, Catholic University Leuven, CBD Solutions, CC Biotechnology, Celanese, Celeri Health, Cellectricon, Cellenkos, Cellerys, Cellevolve Bio, CenSyn, Centogene, Centrexion, Century Therapeutics, Cerecin, Cerecor, CereHealth, Cerevel Therapeutics, Cerveau Technologies, Chamishi Therapeutics, Champalimaud Foundation, Charite Universitatsmedizin Berlin, Charles River Laboratories, Chemify, Chemomab Therapeutics, Chiesi Global Rare Diseases, Children's Hospital at Montefiore, Children's Hospital Boston, Chromocell, Chugai Pharmaceutical, Ciitizen, Cincinnati Children’s Hospital Medical Center, Citizens United for Research in Epilepsy, City of Hope, CK Rizeon, Clario, Clearmind Medicine, ClearPoint Neuro, Clearsky Medical Diagnostics, Cleave Therapeutics, Clene Nanomedicine, Cleveland Clinic, Clexio, CliniFusion, Clintrex Research, CMT Research Foundation, CND Life Sciences, Coave Therapeutics, Cobra Biologics, CODA Biotherapeutics, Code Biotherapeutics, Codiak BioSciences, Cognition Therapeutics, Cohen Veterans Bioscience, Columbia University, CombiGene, Complix, Complutense University of Madrid, Concentric Analgesics, Confo Therapeutics, Contera Pharma, Contineum Therapeutics, Convelo Therapeutics, CorTechs Labs, Coya Therapeutics, CraniUS, Creative Medical Technologies, CRISPR Therapeutics, Cristalia, Critical Path Institute (C-Path), Crossject, CrossLink Bioscience, Cumberland Pharmaceuticals, Curavit Clinical Research, Curebase, Cure Genetics, CURE Pharmaceutical, Curexo, Currax Pharmaceuticals, Cycle Pharmaceuticals, Cyclica, Cynergi Health Partners, Cyntar Ventures, D&D Pharmatech, Daewoong Pharmaceutical, Daiichi Sankyo, DEARhealth, Defender Pharmaceuticals, Defense Advanced Research Projects Agency, Defense Health Agency (US), Delix Therapeutics, Denali Therapeutics, Department of Defense, Department of Veterans Affairs, Dewpoint Therapeutics, DiagnaMed, Diagnostic Biochips, Diagnostic Robotics, DiamiR, Digestome Therapeutics, DiscGenics, Dixi, doc.ai, Dong-A Pharmaceutical, Dr. Reddy's Laboratories, Draeger Safety Diagnostics, Dragonfly Therapeutics, DrChrono, Duke University, Dyno Therapeutics, DZNE German Center for Neurodegenerative Diseases, Eagle Pharmaceuticals, eCential Robotics, Echolight Medical, Editas Medicine, EditForce, Egalet, Eikonizo Therapeutics, Eikonoklastes Therapeutics, Eikon Therapeutics, Eisai, ElectroCore, Eli Lilly, EmbodyBio, Emerald Innovations, EmergeOrtho, EMMAC Life Sciences, Emory University, Empatica, Enamine, Encoded Therapeutics, Endo International, Enigma Biomedical, Ensysce Biosciences, Enterin, Entos Pharmaceuticals, Envisagenics, EpicGenetics, Epilepsy Canada, Epilepsy Foundation (EF), Equilibre BioPharmaceuticals, Erasmus University Medical Center, Esteve, ES Therapeutics, EtectRx, Eterna Therapeutics, Ethypharm, Eton Pharmaceuticals, EuMentis Therapeutics, Eureka Eurostars, Eurofarma, European Innovation Council, European Union, Eversana, EverythingALS Open Innovation Consortium, Evogen, Evolution Research Group, Evonik Industries, Evotec, Exagen Diagnostics, Expesicor, Expressive Neuroscience, ExScientia, Eyam Vaccines and Immunotherapeutics, Facial Pain Research Foundation, FAR Biotech, Feinstein Institute for Medical Research, Ferrer, FightMND, Find Therapeutics, FitBit, Flexion Therapeutics, Florida Atlantic University Research, Fondazione Telethon, Food and Drug Administration (FDA), Forbius, Forge Biologics, Formosa Pharmaceuticals, Fortress Biotech, Foundation to Fight H-ABC, Frametact, FreeMind Group, Fritz Clinic, FUJIFILM Cellular Dynamics, Fundacion Progreso y Salud, Fuzionaire Diagnostics, Gain Therapeutics, GE Healthcare, Geisinger Medical Center, Gen, GeneCode, GeneData, GenEdit, GeneDX, Genentech, GeneQuantum Healthcare, General Genomics, Genetika+, Geneva Foundation, Genomind, Genpharm, Gensaic, Genzyme, Georgetown University, Golden Meditech, Goldfinch Bio, GoodRx, Graviton Bioscience, Grunenthal, GSK, GTx, H1, Hadassah Medical Center, Hainan Sihuan Pharmaceutical, Haisco Pharmaceutical, Halberd, HanAll Pharmaceuticals, Hangzhou Highlightll Pharmaceutical, Happify Health, Harmonic Bionics, Harvard Medical School, Harvard University, Healint, Healx, Helius Medical Technologies, Helsinki University Central Hospital (HUCH) Comprehensive Cancer Center, Hemostemix, Herantis, Heron Therapeutics, Hetero Labs, Higgs Boson Health, Hikma Pharmaceuticals, Honda R&D Americas, Hong Kong Baptist University, HonorHealth, Horizon Europe, Hospital Fondation Adolphe de Rothschild, Hospital for Special Surgery, Hyloris Pharmaceuticals, Hyperfine Research, I-mab, IACTA Pharmaceuticals, IAMA Therapeutics, IBM, Icagen, Icahn School of Medicine at Mount Sinai, Icometrix, Ideal Medical Solutions, Idorsia, IIT-Istituto Italiano di Tecnologia, Iktos, Imbrium Therapeutics, Imeka, Immuneering, Immune Therapeutics, Impel NeuroPharma, Imperial College London, Inagene Diagnostics, INBRAIN Neuroelectronics, Incannex Healthcare, Incyte, Indegene Lifesystems, Inexia, Inflazome, InfuTronix Solutions, Inhibikase Therapeutics, INmune Bio, INNERVIA Bioelectronics, Innodem Neurosciences, Innosuisse, Innovate UK, Inscopix, InSightec, Insilico Medicine, InSilicoTrials, Insitro, InspireMD, Institute for Research in Biomedicine, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute of Molecular and Clinical Ophthalmology Basel, Institute of Neurodegenerative Diseases, Integrated Micro-Chromatography Systems, IntelGenx, Inteligex, Interaxon, International Society of Heart and Lung Transplantation, International Spine Study Group Foundation, Intravacc, Inventia Life Science, Inventum Genetics, Invitae, Ionian University, Ionis Pharmaceuticals, Ipsen, IRBM, IRLAB, Iroko Pharmaceuticals, Irras, iRxReminder, iSchemaView, Ischemix, Isosceles Pharmaceuticals, Israeli National Authority for Technological Innovation, iX Biopharma, J2H Biotech, JADBio, JanOne, Janssen Biotech, Janssen Pharmaceutica NV, Jazz Pharmaceuticals, JCR Pharmaceuticals, Jiangsu Aosaikang Pharmaceutical, Jiangsu NHWA Pharmaceutical, Jnana Therapeutics, Johns Hopkins Medicine (JHM), Johns Hopkins University, Jubilant Biosys, Kahn-Sagol-Maccabi, Karolinska Institute, Karuna Therapeutics, Kazia Therapeutics, KBI BioPharma, Keck School of Medicine of USC, KeifeRx, Keller Army Hospital, Kessler Foundation, KeyWise, KIF1A, Kindeva Drug Delivery, Kineta, Kings College London, Kira Pharmaceuticals, Kissei Pharmaceutical, Kit Check, KK Women’s and Children’s Hospital, Klaria, Knopp Biosciences, Koneksa Health, Koru Medical Systems, Kowa Pharmaceuticals America, KT Corporation, Kurve Technology, Kyverna Therapeutics, Lacerta Therapeutics, Landos Biopharma, LANGaware, Le Bonheur Children's Hospital, Les Laboratoires Servier, Liechti Lab, LifeArc, Ligand Pharmaceuticals, Lineage Cell Therapeutics, Lipidomics Consulting, Lipidor, Lobe Sciences, Lonza, LoQus23 Therapeutics, LTS Lohmann Therapie-Systeme, Lucid Psycheceuticals, Luciole Medical, Lucy Therapeutics, Ludwig Institute for Cancer Research, Lundbeck, Lundquist Institute, Lund University, Lurie Children's Hospital of Chicago, Luxna Biotech, Lyfebulb, Lysogene, Lysosomal Therapeutics, Maastricht University, Mabylon, Magic Leap, Mapi Pharma, MapLight Therapeutics, Marinus Pharmaceuticals, Maruho, Maruishi Pharmaceutical, Masimo, MASORI Therapeutic, Massachusetts General Hospital, Massachusetts Life Sciences Center, Mass General Brigham, Max-Planck, Mayo Clinic, MC10, McGill University, McMaster University, McNeil Consumer Pharmaceuticals, McQuade Center for Strategic Research and Development, MDimune, Medical College of Wisconsin Neuroscience Institute, Medical Developments International, Medical iSight, Medical Product Laboratories, Medical Research Council, Medical University of Innsbruck, Medical University South Carolina, MediciNova, Medidata Solutions, Medipal Holdings, MediPharm Labs, MediSynergics, Medolife Rx, MedRhythms, Medtronic, Melior Pharmaceuticals, Menarini, MentiNova, Merck and Co, Merck KGaA, Mesoblast, Metabolon, MetaSight Diagnostics, Methodist Hospital Houston, Metrion Biosciences, MetVital, Mi-Helper, Michael J Fox Foundation, Michigan State University, Microsoft, MiNA Therapeutics, MindMaze, Mind Medicine, MindShift Compounds, Minoryx Therapeutics, Miravo Healthcare, Mirimus, Mitacs, MitoCanada Foundation, Mitochondrial Innovation Initiative, Mitochon Pharmaceuticals, MitoSense, Mitsubishi Tanabe Pharma, MOBILion Systems, Modag, Modalis Therapeutics, Molecular Health, Moleculera Labs, Monte Rosa Therapeutics, Montreal Neurological Institute-Hospital, Motorpharma, Motric Bio, Mount Sinai Medical Center, Movendo Technology, MRI Interventions, MSD, MThera Pharma, Multiple Sclerosis Society of Canada, Mundipharma, Muscular Dystrophy Association, Myeloproliferative Neoplasm Research Consortium, Mylan Laboratories, MYND Life Sciences, Myrtelle, Myung In Pharm, n-Lorem Foundation, Nanna Therapeutics, NanoDx, Nanoform, NanoVibronix, NASA, NATA, National Center for Advancing Translational Sciences (NCATS), National Human Genome Research Institute, National Institute of Allergy and Infectious Diseases, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Drug Abuse (NIDA), National Institutes of Health, National Medical Products, National Organization for Rare Disorders, National Resilience, National University of Ireland, Galway (NUI Galway), National Yang-Ming University, Neogap Therapeutics, Neo Medical, Neotope, Nephron Dx, Nephron Pharmaceuticals, NervGen Pharma, NE Scientific, Nestle Health Science, NetraMark, NeuCyte, Neumentum, Neumora Therapeutics, NeuPath Health, NeurAegis, NeuraLight, Neuramedy, Neuraxpharm, Neurelis, Neurgain Technologies, Neurimmune Therapeutics, Neuro3 Therapeutics, Neuro42, NeuroBo Pharmaceuticals, Neurochase, Neurocrine Biosciences, NeuroCycle Therapeutics, NeuroFront, Neurogene, NeuroGenesis, Neurolief, Neurolixis, NeuroLogica, Neuron23, Neuronasal, Neurona Therapeutics, NeuroNexus, Neuronic, Neuronoff, NeuroOne, NeuroPace, Neuropore Therapies, NeuroScience Associates, NeuroSense Therapeutics, NeuroSigma, NeuroTracker, NeuroTrauma, Newel Health, Newly Institute, Newron Pharmaceuticals, NHL Alumni Association, Nico, Nitrome Biosciences, NKGen Biotech, Noema Pharma, Northeastern University, Northern Biomedical Research, North Med, NorthShore University HealthSystem, Northwestern University, Novaremed, Novartis, Noveome Biotherapeutics, Novoron Bioscience, NRG Therapeutics, Nuance Pharma, Nuformix, Numares, Numerate, NurExone Biologic, Nurosene, NurrOn Pharmaceuticals, Nutriband, NuVasive, Nvidia, nView Medical, NysnoBio, NYU Langone Medical Center, Oakrum Pharma, ObvioHealth, Ocular Therapeutix, Oculogica, Ohio State Innovation Foundation, Ohio State University, Oklahoma Medical Research Foundation, Olaris, Olatec Therapeutics, Oncodesign, Oncotelic, OncoZenge, Onegevity, OnFace, Ono Pharmaceutical, ONWARD Medical, OptiNose, Orchard Therapeutics, Organo Therapeutics, Orion, Orionis Biosciences, Orphazyme, Orthofix Medical, OrthoRebirth, Oryzon, Oslo University Hospital, Osmotica Pharmaceuticals, Osseus Fusion Systems, Ovensa, Ovid Therapeutics, Owl Therapeutics, OWP Pharmaceuticals, Oxford Biodynamics, Oxyrane UK, Ozop Energy Solutions, Pacific Biosciences, Pain Care Labs, PainQx, Panaxia, Parkinson's Disease Foundation, Parkinson's UK, Parkinsons Disease Foundation, Pasithea Therapeutics, Passage Bio, PathMaker Neurosystems, Pathway Rx, Patient-Centered Outcomes Research Institute, PEAR Therapeutics, Peptide Logic, PeptiDream, Pfizer, Pharmaleads, Pharmanovia, PharmaTher, Pharma Two B, Pharmazz, PharmEnable, Pheno Therapeutics, Philips, Phoenix PharmaLabs, PhoreMost, PicnicHealth, PINC AI Applied Sciences, Planet Green BioTechnology, Plexium, Plus Therapeutics, Polpharma, Polyrizon, Praxis Precision Medicines, PreCerv, PrecisionLife, Prevail Therapeutics, Primary Peptides, PrinterPrezz, Procaps, Progentec Diagnostics, Project ALS, Prometheus Laboratories, Propella Therapeutics, Prothena, Protxx, PsychoGenics, Psylo, PTC Therapeutics, Purdue Pharma, Purespring Therapeutics, PurMinds NeuroPharma, Q-Gen Cell Therapeutics, Q-State Biosciences, Q30 Innovations, Qiagen, Quadram Institute, Quansys Biosciences, Quantiphi, Queensland Institute of Medical Research (QIMR), Quell Therapeutics, Quotient, QurAlis, rAAVen Therapeutics, Ractigen Therapeutics, Rafa Laboratories, Rafa Pharmaceuticals, Rainwater Charitable Foundation, RapidAI, RBC Medical Innovations, ReAlta Life Sciences, Recro Pharma, Recursion, Redwire, Regenacy Pharmaceuticals, Regenerative Medicine of Latin America, Regeneron Pharmaceuticals, Regenexx, Regenstrief Institute, Regenxbio, Regulus Therapeutics, Releviate Therapeutics, Repertoire Immune Medicines, RespireRx Pharmaceuticals, restor3d, RetroBrain, Rgenta Therapeutics, RH Nanopharmacuticals, Rho, Rhoshan Pharmaceuticals, Rigel Pharmaceuticals, Rigshospitalet, Roche, RogCon Biosciences, Rosalind Franklin University of Medical Sciences, Rose F Kennedy Intellectual and Developmental Disabilities Research Center, Rosies Base, Roswell Biotechnologies, Royal Philips Electronics, Rune Labs, Rutgers Cancer Institute of New Jersey, Rutgers University, Safe Orthopaedics, Sage Therapeutics, Saitama Medical University Hospital, Salus Pharma, Samsung Biologics, Sandoz, Sangamo Therapeutics, Sanofi, Santa Clara University, Sarepta Therapeutics, SATT Conectus Alsace, Sawai Pharmaceuticals, Schenker Technologies, Schrodinger, Scilex Pharmaceuticals, SciNeuro Pharmaceuticals, Scipher Medicine, SciSparc, Scopus BioPharma, Scribe Therapeutics, Scripps Research Institute, Sean M Healey & AMG Center for ALS, SeaSpine, Seattle Children's Therapeutics, Secarna Pharmaceuticals, Seelos Therapeutics, Selexis, Selonterra, Selvita, Sengenics, Sensome, Senti Biosciences, SeraNovo, SERB Pharmaceuticals, Seurat Therapeutics, SFJ Pharmaceuticals, Shanghai Accurature Diagnostics, Shape Therapeutics, Sheffield Institute for Translational Neuroscience, Shina Systems, Shionogi, Shirley Ryan AbilityLab, Sibylla Biotech, Siemens Healthineers, Silo Pharma, SilverCloud Health, Simcere Pharmaceuticals, Sinopia Biosciences, SipNose, Sirion Biotech, Sironax, SiteOne Therapeutics, SKAN Research Trust, SK Biopharmaceuticals, SK Chemicals, Skye Bioscience, Skyhawk Therapeutics, SkyWater Technology, Smithfield BioScience, Society of NeuroInterventional Surgery, Society of Vascular and Interventional Neurology, Solasia Pharma, Sorrento Therapeutics, Sosei Heptares, Sovargen, Spark Therapeutics, Specialised Therapeutics, Spectrum Spine, Sperogenix Therapeutics, Spinal Resources, Spineart, SpineCraft, Spinogenix, Stanford University, Starton Therapeutics, Statera Biopharma, State University of New York, Stealth BioTherapeutics, StemoniX, Stem Pharm, Stevanato, Stoke Therapeutics, Stony Brook University, Stratus Research Labs, StrideBio, Sumitomo Dainippon Pharma, Sunnybrook Research Institute, Sunovion Pharmaceuticals, Sun Pharmaceutical, SwanBio Therapeutics, Swedish Orphan Biovitrum, Swedish Research Council, Swysh, Synaffix, Synaptogenix, SynPhNe, Taiwan Liposome Company, Takeda Pharmaceutical, Target ALS Foundation, Tautomer Bioscience, Taysha Gene Therapies, Teijin, Temedica, Tenacia Biotechnology, Terran Biosciences, Tetragenetics, Tetraphase Pharmaceuticals, Teva Pharmaceutical Industries, Tevard Biosciences, TG Therapeutics, The Cure Parkinson's Trust, Theradaptive, Theranica Bio-Electronics, TheraPanacea, Therapeutic Solutions International, Therapix Bio, The Regents of the University of California, Thermo Fisher Scientific, The Silverstein Foundation for Parkinson's, Thomas Jefferson University, TLC BioSciences, Tomahawk Charitable Solutions, TONIX Pharmaceuticals, Total Brain, Translational Genomics Research Institute, Treeway, Trevi Therapeutics, Trillium Therapeutics, Twist Bioscience, twoXAR, Tymora Analytical Operations, Ubiquigent, UCB, Uman Diagnostics, UniQure, University Ann & Robert H. Lurie Children’s Hospital, University College London, University Health Network, University Medical Center Utrecht, University of Alabama at Birmingham, University of Alberta, University of Antwerp, University of Arizona, University of Auckland, University of Barcelona, University of Bath, University of British Columbia, University of Calgary, University of California, Davis, University of California, San Diego, University of California Berkeley, University of California Irvine, University of California Riverside, University of California San Francisco, University of Chicago, University of Colorado, University of Copenhagen, University of Edinburgh, University of Florida, University of Glasgow, University of Helsinki, University of Hong Kong, University of Illinois, University of Iowa, University of Kentucky, University of Leeds, University of Lethbridge, University of Marburg, University of Maryland School of Medicine, University of Massachusetts Medical School, University of Memphis, University of Miami, University of Miami Miller School of Medicine, University of Michigan, University of Montreal, University of Nebraska, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Rochester, University of Rochester Medical Center, University of Rome, University of Sheffield, University of Sydney, University of Texas Southwestern Medical Center, University of Toronto, University of Tubingen, University of Washington, University of Wollongong, Unlearn, Uppsalagruppen Medical, Uppsala University, Upside Health, US Army, US Army Medical Research and Material Command, Valence Discovery, Vanderbilt University, Vandria, Vastrax, Vaxxinity, Vect-Horus, VectorY Therapeutics, Vectura, Veeva Systems, Veltmeyer MD, Ventus Therapeutics, Verana Health, Verge Genomics, VeriSIM Life, Vernalis, Vertex Pharmaceuticals, Viela Bio, Vincere Biosciences, Vinnova, Virginia Commonwealth University, Virpax Pharmaceuticals, Visiopharm, VistaGen Therapeutics, Vitruvias Therapeutics, Viz.ai, VoxNeuro, Voyager Therapeutics, Vyant Bio, Vyripharm, Wake Forest University, Wake Research Associates, Walter Reed Army Institute of Research, Wanbang Biopharmaceuticals, WAVE Life Sciences, WCTE, Weill Cornell Medical College, Weizmann Institute, Willow Biosciences, Winhealth Pharma Group, WinterLight Labs, Wisconsin Health Information Organization, Woolsey Pharmaceuticals, WraSer Pharmaceuticals, Wren Therapeutics, Wuxi Apptec Laboratory Services, Wuxi STA, Wyss Center, X-chem, Xenon Pharmaceuticals, XRHealth, Xspire Pharma, Yale School of Medicine, Yale University, Yeda Research and Development Company, Yissum Research Development, Yumanity Therapeutics, Zambon, Zelira Therapeutics, Zentiva, Zeta Surgical, Zhittya Genesis Medicine, Zhongze Therapeutics, Zimmer Biomet, Zogenix, ZyVersa Therapeutics, ZZ Biotech

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.